Table 4.
Author, year | Design | Subjects | Intervention type and duration | Outcome |
---|---|---|---|---|
Clifton-Bligh, 2001 42 | RCT with 3 groups. One month of placebo period followed by 6 months of treatment and 1 month of placebo washout. Placebo periods were single blinded. |
|
The three doses of Rimostil were: 28 mg/d, 57 mg/d, and 85.5 mg/d of isoflavones.
Duration: 6 months |
BMD of radius and ulna increased significantly for women in medium and high treatment groups.
Safety: endometrial thickness did not change significantly during treatment. |
Atkinson, 2004 45 | RCT with 2 groups: Placebo or isoflavone tablet |
|
Promensil tablet was uses as treatment. One tablet per day in intervention group.
Duration: 12 months |
Loss of lumbar spine BMC and BMD significantly lower in women taking supplement.
Bone formation markers significantly increased in supplement group. |
Schult, 2004 43 | RCT with 3 groups: Promensil®, Rimostil®, and placebo |
|
Promensil: Red clover extract with 41 mg isoflavones per tablet
Rimostil: Red clover extract with 28.6 mg isoflavones per tablet. Two tablets per day of each treatment. Duration: 12 weeks |
No significant differences between groups in bone turnover markers |
Abbreviations: RCT=Randomized Controlled Trial, BMD=bone mineral density, BMC=bone mineral content